Xeris Biopharma Holdings, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K, dated August 8, 2024, serves as a current report for Xeris Biopharma Holdings, Inc. (XERS). The filing references a press release issued on the same date detailing the Company's results of operations and business highlights for the three and six months ended June 30, 2024.
Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained within the referenced press release (Exhibit 99.1) but are not embedded in the body of this Form 8-K.
Material Changes
The filing does not explicitly list material changes versus prior periods within the text provided. It directs readers to the attached press release for operational results and business highlights.
Guidance, Outlook, and Risks
Management commentary, guidance, outlook, and specific risk factors are not detailed in this filing text. The document notes that the information in Item 2.02 and Exhibit 99.1 is furnished but not deemed "filed" for purposes of Section 18 of the Exchange Act, nor is it incorporated by reference except as expressly set forth.
Key Facts for Investor Verification
- Verify the specific financial results for the three and six months ended June 30, 2024, by reviewing Exhibit 99.1 (Press Release dated August 8, 2024).
- Confirm the Company's status as an emerging growth company, as indicated by the check mark in the filing.
- Note that the financial data in this 8-K is not legally "filed" under Section 18 of the Exchange Act, limiting liability protections compared to standard periodic reports.
- Review the press release for any updates on clinical trials or business developments not captured in this summary.